O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+9.47%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$6.34B
AUM Growth
+$6.34B
(-0.66%)
Cap. Flow
-$66.5M
Cap. Flow
% of AUM
-1.05%
Top 10 Holdings %
Top 10 Hldgs %
40.11%
Holding
139
New
17
Increased
27
Reduced
20
Closed
14
Top Buys
| 1 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
$182M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$104M |
| 3 |
uniQure
QURE
|
$70.2M |
| 4 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
$67.5M |
| 5 |
Natera
NTRA
|
$59.2M |
Top Sells
| 1 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
$272M |
| 2 |
Guardant Health
GH
|
$118M |
| 3 |
Viatris
VTRS
|
$66.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$64M |
| 5 |
Humana
HUM
|
$55.9M |
Sector Composition
| 1 | Healthcare | 97.38% |
| 2 | Financials | 1.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HARP
51
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $31.8M | 0.49% | 2,446,409 | – | – |
|
52
CareDx
CDNA
$727M
| $29.8M | 0.46% | 827,600 | – | – |
|
|
OBSV
53
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $29.5M | 0.46% | 2,605,531 | – | – |
|
|
CLVS
54
DELISTED
Clovis Oncology, Inc.
CLVS
| $28.5M | 0.44% | 1,913,234 -919,066 | -32% | -$13.7M |
|
55
Xtant Medical Holdings
XTNT
$83.3M
| $27.6M | 0.43% | 9,207,012 | – | – |
|
56
Gilead Sciences
GILD
$140B
| $27.1M | 0.42% | 401,600 -42,200 | -10% | -$2.85M |
|
|
57
Viatris
VTRS
$12.3B
| $26.1M | 0.41% | 1,373,305 -3,488,495 | -72% | -$66.4M |
|
58
Krystal Biotech
KRYS
$4.27B
| $25.9M | 0.4% | 642,006 +582,796 | +984% | +$23.5M |
|
|
ENDP
59
DELISTED
Endo International plc
ENDP
| $25.4M | 0.39% | 6,165,464 | – | – |
|
60
Corvus Pharmaceuticals
CRVS
$428M
| $24.6M | 0.38% | 6,565,685 +598,101 | +10% | +$2.24M |
|
61
Adverum Biotechnologies
ADVM
$64.6M
| $23.3M | 0.36% | 1,960,200 +717,000 | +58% | +$8.53M |
|
62
Aurinia Pharmaceuticals
AUPH
$1.58B
| $23.2M | 0.36% | 3,531,002 +381,192 | +12% | +$2.51M |
|
|
ONCE
63
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $22.5M | 0.35% | +219,900 | New | +$22.5M |
|
64
Amgen
AMGN
$155B
| $22.5M | 0.35% | 122,100 | – | – |
|
|
GNFT
65
Genfit
GNFT
$200M
| $22.2M | 0.34% | 1,125,607 -104,707 | -9% | -$2.07M |
|
66
KALA BIO
KALA
$78.8M
| $22M | 0.34% | 3,447,840 | – | – |
|
67
Alcon
ALC
$39.5B
| $21.7M | 0.34% | +351,380 | New | +$21.7M |
|
68
Biogen
BIIB
$19.4B
| $20.5M | 0.32% | 87,700 | – | – |
|
69
SI-BONE Inc
SIBN
$719M
| $20M | 0.31% | 985,368 | – | – |
|
70
Karyopharm Therapeutics
KPTI
$61.7M
| $18.9M | 0.29% | +3,148,475 | New | +$18.9M |
|
71
Synlogic
SYBX
$17M
| $18.5M | 0.29% | 2,029,996 | – | – |
|
72
Rhythm Pharmaceuticals
RYTM
$6.85B
| $17.3M | 0.27% | 787,300 | – | – |
|
73
Verrica Pharmaceuticals
VRCA
$52.8M
| $17.2M | 0.27% | 1,479,733 | – | – |
|
74
Novo Nordisk
NVO
$251B
| $16.8M | 0.26% | 330,000 | – | – |
|
|
SVA
75
DELISTED
Sinovac Biotech, Ltd
SVA
| $16.6M | 0.26% | 2,839,500 | – | – |
|